Chapter 4729-11 Controlled Substance Schedules
(B) "Schedules" mean controlled substance schedules I, II, III, IV, and V, respectively as defined in division (BB) of section 3719.01 of the Revised Code and subject to the findings for the placement on schedules as defined in Controlled Substances Act of 1970, 84 Stat. 1242, 21 U.S.C. 812 (July 9, 2012).
(C) "Synthetic" unless specifically excepted or unless listed in another schedule, means any substance, material, compound, mixture, or preparation that contains any quantity of a substance made artificially by chemical reaction.
(D) "Pharmacophore" means the portion of a chemical structure that confers the activity of the substance.
(E) "A report from an established forensic laboratory" means a laboratory report from the bureau of criminal identification and investigation, or a laboratory operated by another law enforcement agency, or a laboratory established by or under the authority of an institution of higher education that has its main campus in this state and that is accredited by the association of American universities or the north central association of colleges and secondary schools, primarily for the purpose of providing scientific services to law enforcement agencies and signed by the person performing the analysis as defined in division (A) of section 2925.51 of the Revised Code.
(F) "Synthetic cannabinoids" are drugs commonly found in herbal incense products (common names include but are not limited to: spice, blaze, devil's advocate, genie, smoke, sense, zohai, spike 99, and K2) that may mimic the effects of delta-9-tetrahydrocannabinol (THC), an active central nervous system constituent compound of marijuana.
(G) "Synthetic cathinones" are stimulants related to cathinone, the psychoactive substance found in the shrub catha edulis (khat). Synthetic cathinones (common names include, but are not limited to: research chemicals, plant food, and bath salts), which are beta-keto phenethylamine derivatives, produce pharmacological effects similar to methamphetamine.
(A) The state board of pharmacy hereby schedules the following synthetic cannabinoid compounds as schedule I controlled substance hallucinogens:
(1) PB-22 (chemical name: quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) ;
(2) 5-Fluoro-PB-22 (chemical name: quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) .
(B) Except as otherwise provided in section 3719.41 of the Revised Code, any compound that meets at least three of the following pharmacophore requirements to bind at the CB1 and CB2 receptors, as identified by a report from an established forensic laboratory, is a schedule I controlled substance hallucinogen:
(1) A chemical scaffold consisting of substituted or non-substituted ring structures that facilitate binding of required elements (such as: indole compounds, indazoles, benzimidazoles or other ring types);
(2) Alkyl or aryl side chain off the chemical scaffold providing hydrophobic interaction with the CB1 and CB2 receptors;
(3) Carbonyl or ester or equivalent for hydrogen bonding;
(4) Cyclohexane, naphthalene ring, substituted butanamide or equivalent for steric requirements for CB1 and CB2 receptor binding.
(C) Except as otherwise provided in section 3719.41 of the Revised Code, any compound that contains the structural requirements of the cathinone pharmacophore, as identified by a report from an established forensic laboratory, is a schedule I controlled substance.
(D) Except as otherwise provided in section 3719.41 of the Revised Code, any compound that meets the following fentanyl pharmacophore requirements to bind at the mu receptor, as identified by a report from an established forensic laboratory, is a schedule I controlled substance opiate:
(1) A chemical scaffold consisting of:
(a) A five, six or seven member ring structure containing a nitrogen, whether or not further substituted; and
(b) An attached nitrogen to the ring, whether or not that nitrogen is enclosed in a ring structure, including an attached aromatic ring or other lipophilic group to that nitrogen;
(2) A polar functional group attached to the chemical scaffold, including but not limited to, a hydroxyl, ketone, amide or ester;
(3) An alkyl or aryl substitution off the ring nitrogen of the chemical scaffold; and
(4) The compound has not been approved for medical use by the United States food and drug administration.
(E) 6-monoacetylmorphine (6-MAM) is a schedule I controlled substance opium derivative.
(F) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (U-47700) is a schedule I controlled substance opium derivative.
Five Year Review (FYR) Dates: 04/17/2019
Promulgated Under: 119.03
Statutory Authority: 3719.44, 3719.28, 4729.26
Rule Amplifies: 3719.44, 3719.41
Prior Effective Dates: 4/17/2014, 10/24/14, 1/15/2016, 5/4/16 (Emer)
The state board of pharmacy hereby schedules the following compounds as Schedule IV controlled substances:
2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexanol hydrochloride, its salts, isomers (including the optical and geometric isomers), salts of isomers, and all isomeric configurations of possible forms including tramadol.
All editions, with cumulative changes, if any, of the following reference works are recognized and approved by the state board of pharmacy:
(A) "Drug Facts and Comparisons";
(B) "Martindale: The Extra Pharmacopoeia";
(C) "Remington's Pharmaceutical Sciences";
(D) "United States Dispensatory";
(E) "United States Pharmacopeia/National Formulary" ("USP/NF");
(F) "American Hospital Formulary Service Drug Information" ("AHFS Drug Information") ;
(G) A controlled substance reference table compiled by the state board of pharmacy using any of the reference works listed in this rule. This table shall be made available on the board's web site.
Five Year Review (FYR) Dates: 03/17/2019
Promulgated Under: 119.03
Statutory Authority: 3715.69, 3719.28, 4729.26
Rule Amplifies: 2925.01, 3715.01, 3719.01, 4729.01
Prior Effective Dates: 2/15/82, 2/15/95, 1/1/10
A schedule V controlled substance product which is not a prescription drug as determined under the "Federal Food, Drug and Cosmetic Act" may be sold at retail by a pharmacist without a prescription to a purchaser at retail, provided that:
(A) The sale is made only by a pharmacist or a pharmacy intern under the direct supervision of a pharmacist and not by a nonpharmacist employee even if under the supervision of a pharmacist (although after the pharmacist has fulfilled his professional and legal responsibilities in this section, the actual cash, credit transaction, or delivery may be completed by a nonpharmacist).
(B) The purchaser is at least eighteen years of age.
(C) The pharmacist requires every purchaser of a controlled substance under this rule not known to him to furnish suitable identification (including proof of age where appropriate).
(D) A bound record book is maintained which contains the true name and complete address of the purchaser, the legible signature of the purchaser, the name and quantity of controlled substances sold, the date of each sale, and the name and legible initials of the pharmacist who sold the controlled substance at retail. This book shall be maintained for a period of three years from the date of the last transaction and must be made available for inspection and copying by persons authorized to enforce the federal and state drug laws.
(E) The schedule V controlled substance product is sold at retail.
(F) Not more than two hundred forty milliliters (eight ounces) nor more than forty-eight solid dosage units of any schedule V controlled substance product containing opium, nor more than one hundred twenty milliliters (four ounces) nor more than twenty-four solid dosage units of any other narcotic controlled substance may be sold at retail to the same purchaser in any consecutive forty-eight-hour period.
(G) Not more than one hundred solid dosage units of any schedule V controlled substance stimulant product may be sold to any one person in any consecutive thirty-day period.
(H) The schedule V controlled substance is sold at retail for a legitimate medical need and the purchaser furnishes information to the pharmacist which establishes the legitimate medical need for the controlled substance.
119.032 review dates:
Promulgated Under: 119.03
Statutory Authority: 3719.28, 4729.26
Rule Amplifies: 3719.05, 4729.28, 4729.51
Prior Effective Dates: 08/16/1994 (Emer), 11/25/1994, 03/01/1999, 03/31/2000